Related Experiment Video
Updated: Oct 13, 2025

Author Spotlight: Isolation and Culture of Primary Synovial Macrophages and Fibroblasts from Murine Arthritis Tissue
Published on: February 24, 2023
Targeted therapy of rheumatoid arthritis via macrophage repolarization
Xu Zhou1, Dandan Huang2, Runkong Wang1
1Sichuan Provincial Orthopedic Hospital, Chengdu, China.
Abstract:
The polarization of macrophages plays a critical role in the physiological and pathological progression of rheumatoid arthritis (RA). Activated M1 macrophages overexpress folate receptors in arthritic joints. Hence, we developed folic acid (FA)-modified liposomes (FA-Lips) to encapsulate triptolide (TP) (FA-Lips/TP) for the targeted therapy of RA. FA-Lips exhibited significantly higher internalization efficiency in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells than liposomes (Lips) in the absence of folate. Next, an adjuvant-induced arthritis (AIA) rat model was established to explore the biodistribution profiles of FA-Lips which showed markedly selective accumulation in inflammatory paws. Moreover, FA-Lips/TP exhibited greatly improved therapeutic efficacy and low toxicity in AIA rats by targeting M1 macrophages and repolarizing macrophages from M1 to M2 subtypes. Overall, a safe FA-modified liposomal delivery system encapsulating TP was shown to achieve inflammation-targeted therapy against RA via macrophage repolarization.
Insights
This study developed folic acid-modified liposomes carrying triptolide to target M1 macrophages in rheumatoid arthritis. This targeted therapy effectively reduced inflammation and toxicity in rats by repolarizing macrophages.
Area of Science:
- Immunology
- Nanomedicine
- Pharmacology
Background:
- Macrophage polarization is crucial in rheumatoid arthritis (RA) pathogenesis.
- M1 macrophages, prevalent in RA, overexpress folate receptors.
- Targeted delivery systems are needed to modulate macrophage function in RA.
Purpose of the Study:
- To develop folic acid-modified liposomes (FA-Lips) encapsulating triptolide (TP) for targeted RA therapy.
- To evaluate the efficacy and safety of FA-Lips/TP in an adjuvant-induced arthritis (AIA) rat model.
- To investigate the mechanism of macrophage repolarization from M1 to M2 subtypes.
Main Methods:
- Fabrication and characterization of folic acid-modified liposomes (FA-Lips) encapsulating triptolide (TP).
- In vitro assessment of liposome internalization in LPS-stimulated RAW 264.7 cells.
- In vivo evaluation of FA-Lips biodistribution, therapeutic efficacy, and toxicity in an AIA rat model.
Main Results:
- FA-Lips demonstrated significantly higher cellular uptake than unmodified liposomes.
- FA-Lips selectively accumulated in the inflamed paws of AIA rats.
- FA-Lips/TP treatment significantly improved therapeutic outcomes and reduced toxicity in AIA rats by targeting M1 macrophages and promoting M2 repolarization.
Conclusions:
- Folic acid-modified liposomes offer a promising targeted delivery system for RA therapy.
- FA-Lips/TP effectively targets M1 macrophages and repolarizes them to an anti-inflammatory M2 phenotype.
- This approach provides a safe and effective strategy for inflammation-targeted therapy in rheumatoid arthritis.

